	US 12,071,480 B2
	CD47 antibodies and uses thereof for treating cancer
Shyra Gardai, Bothell, WA (US); Matthew Levengood, Bothell, WA (US); Vivian Trang, Lynnwood, WA (US); Lori Westendorf, Bothell, WA (US); Christopher Carosino, Duvall, WA (US); Che Leung-Law, Bothell, WA (US); and Michael Feldhaus, Boston, MA (US)
Assigned to Seagen Inc., Bothell, WA (US)
Filed by Seagen Inc., Bothell, WA (US)
Filed on Oct. 20, 2021, as Appl. No. 17/505,911.
Application 17/505,911 is a division of application No. 16/203,809, filed on Nov. 29, 2018, granted, now 11,180,552.
Claims priority of provisional application 62/593,712, filed on Dec. 1, 2017.
Prior Publication US 2022/0135674 A1, May 5, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/50 (2013.01); C07K 2319/73 (2013.01)]

33 Claims

1. A method for treating a CD47-expressing cancer in a subject, comprising administering to the subject a therapeutically effective amount of an anti-CD47 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises a light chain variable region and a heavy chain variable region, wherein the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 selected from SEQ ID NOs: 16, 17, 18, 31, 32, and 33; SEQ ID NOs: 16, 17, 18, 34, 35, and 33; SEQ ID NOs: 16, 20, 18, 31, 32, and 33; SEQ ID NOs: 16, 20, 18, 34, 35, and 33; SEQ ID NOs: 16, 17, 18, 31, 32, and 36; and SEQ ID NOs: 16, 20, 18, 31, 32, and 36, wherein the heavy chain variable region comprises an amino acid sequence with at least 97% identity to an amino acid sequence selected from SEQ ID NOs: 3 and 7, and wherein the light chain variable region comprises an amino acid sequence with at least 85% identity to an amino acid sequence selected from SEQ ID NOs: 11, 12, 13, 14, and 15.